Summary
Background Circulating proteins play essential roles in numerous complex diseases, yet our understanding of the genetic influences on inflammation and cardiovascular-related proteins in non-European isolated populations remains sparse. Here, we aimed to characterise the genetic architecture of plasma protein biomarkers in the Greenlandic population.
Methods Using combined data from Greenlandic population cohorts (n=3,707 individuals), including genotypes and plasma proteomics (177 proteins) from Olink Target 96 Inflammation and Cardiovascular II panels, we performed a protein quantitative trait loci (pQTL) study using a linear mixed model, accounting for relatedness and population structure.
Findings Mapping of 177 plasma proteins in 3,707 adult Greenlandic individuals (mean age 47.9; 54.5% female) reveal 251 primary pQTLs, 235 additive (92 cis and 143 trans) and 16 recessive (1 cis and 15 trans), 48 secondary pQTLs, and 70 novel pQTLs (28%). We demonstrate a higher proportion of variance in protein levels explained in Greenlanders compared to Europeans from the UK Biobank (e.g. IL-27, IgGFcRII-b, IL-16, and Gal-9). We describe changes in expression of inflammation and cardiovascular-related proteins associated with known high impact Arctic-specific variants, including in CPT1A, TBC1D4, HNF1A, LDLR, and PCSK9.
Interpretation These findings highlight the importance of genome-wide plasma proteomic analyses in Greenlanders, and diverse populations in general, with implications for biomarker and therapeutic target development.
Funding Novo Nordisk Foundation, The Independent Research Fund Denmark, and Karen Elise Jensen Foundation.
Evidence before this study Recent affinity-based proteomic studies have been performed in large European biobank-scale cohorts such as the UK Biobank and deCODE. Several smaller-scale studies have also been performed in isolated European populations, e.g. MANOLIS and Pomak (Hellenic), Orkney (Scotland), and Vis (Croatia). Studies in non-European populations are also beginning to emerge, including in the China Kadoorie Biobank. Studies performed in diverse populations can identify population-specific variants in genes implicated in regulating the expression of proteins, which may be causally linked to inflammation and cardiovascular disease. In particular, small and historically isolated populations, such as the Greenlandic population, are more likely to harbour common variants with larger effect sizes that may contribute to health and disease.
Added value of this study This study reports 251 primary protein quantitative trait loci (pQTLs) associated with the abundance of 177 plasma proteins, 28% of which have not been previously reported. We identified 48 additional pQTLs in a secondary conditional analysis. We identified novel pQTLs that were common in Greenland, but rare globally (e.g. ST1A1, DCN). We found common pQTLs which explained a substantial proportion of variance (>30%) in protein abundance (e.g. IL-27, IgGFcRIIb, IL-16, Gal-9) when compared to Europeans. We examined differences in protein abundance in carriers of Arctic-specific variants (e.g. CPT1A, TBC1D4, HNF1A, LDLR, PCSK9) which are implicated in lipid metabolism and cardiometabolic disease, revealing underlying biological mechanisms.
Implications of all the available evidence Given that both genetics and the environment affect protein levels causally linked to disease, it is crucial to perform genome-wide association studies in smaller populations of diverse genetic ancestry to ensure equity in genetic discovery. Investigating the effect of previously identified Arctic-specific variants on protein expression revealed links to therapeutic targets for metabolic disease, which may have implications for the health care system in Greenland and beyond, including access to treatment.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Novo Nordisk Foundation, Independent Research Fund Denmark, and Karen Elise Jensen Foundation
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study has received ethical approval from the Science Ethics Committee in Greenland. The study was conducted in accordance with the Declaration of Helsinki, second revision. All participants gave written informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Figure 1 and 2 revised.
Data Availability
Summary data from the study may be available by reasonable request to the authors.
